Paper Details

  1. Home
  2. Paper Details

Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.

Author: BarcziEniko, BohacsAniko, EszesNoemi, HejdukKarel, Kolonics-FarkasAbigel, MüllerVeronika, StarobinskiLivia, VasakovaMartina

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nintedanib treatment for idiopathic pulmonary fibrosis showed potential benefits in patients with severely impaired lung function, offering hope for improving outcomes in a challenging patient population.
Paper Details　
Original Abstract of the Article :
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases with limited survival. The effect of IPF therapy in patients with severely impaired lung function is not well established. The aim of this study was to characterize IPF patients with a forced vital capacity (FVC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12325-019-00906-9

データ提供：米国国立医学図書館（NLM）

Nintedanib: A Potential Treatment for Idiopathic Pulmonary Fibrosis (IPF)

This study investigates the effectiveness and safety of nintedanib, a drug used to treat idiopathic pulmonary fibrosis (IPF), in patients with severely impaired lung function. The researchers analyzed data from Hungarian patients diagnosed with IPF, comparing the outcomes of patients with a forced vital capacity (FVC) <50% (group 1) and those with FVC 50-60% predicted (group 2). Their findings suggest that nintedanib might offer some benefit to patients with functionally advanced IPF, although the study calls for further research to confirm these observations.

Nintedanib: A Potential Option for Advanced IPF

This study provides preliminary evidence suggesting that nintedanib might be beneficial for patients with functionally advanced IPF. While further research is needed to confirm these findings, the study offers a glimmer of hope for patients with severely impaired lung function.

Navigating the Challenges of IPF: Hope for Improved Treatment

This study underscores the ongoing challenges in treating IPF, a debilitating lung disease with limited treatment options. The study's findings offer a potential avenue for improving treatment for patients with advanced IPF, but further research is needed to fully assess the drug's efficacy and safety in this population.

Dr. Camel's Conclusion

This study highlights the importance of ongoing research in seeking better treatment options for debilitating diseases like IPF. While further studies are needed to confirm the efficacy of nintedanib in advanced IPF, this research offers a ray of hope for patients grappling with this challenging condition.
Date :
  1. Date Completed 2020-05-06
  2. Date Revised 2020-05-06
Further Info :

Pubmed ID

30877478

DOI: Digital Object Identifier

10.1007/s12325-019-00906-9

Related Literature

Article Analysis
・Effects of nintedanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.